Siolta Therapeutics is a clinical-stage biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
Siolta is on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines.
Siolta Therapeutics was founded in 2016 by Susan Lynch, and Nikole Kimes, in partnership with Samir Kaul (Khosla Ventures). The company is headquartered in San Francisco, California.
Siolta leverages their deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases.
Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in targeted populations.
Siolta's blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform that represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.
Siolta has raised $30M in Series B round on Sep 22, 2020. Backers included Khosla Ventures, Marc Benioff, Seventure (Health for Life Capital Fund), SymBiosis, and Global Brain (Kirin Health Innovation Fund/GB-VII).